CervoMed Inc. Files 8-K on Financials

TL;DR

CervoMed dropped its 8-K, check the financials for April 1st.

AI Summary

CervoMed Inc. filed an 8-K on April 5, 2024, reporting on its results of operations and financial condition as of April 1, 2024. The filing includes financial statements and exhibits related to the company's performance.

Why It Matters

This 8-K filing provides crucial updates on CervoMed Inc.'s financial health and operational results, which are essential for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Numbers

• 001-37942 — SEC File Number (Identifies the company's filing with the SEC.)
• 30-0645032 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• 20 Park Plaza, Suite 424 (location) — Business Address
• Boston, Massachusetts (location) — Business Address City and State
• 02116 (location) — Business Address Zip Code
• Diffusion Pharmaceuticals Inc. (company) — Former Company Name
• RestorGenex Corp (company) — Former Company Name
• Stratus Media Group, Inc (company) — Former Company Name

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20240405_8k.htm (8-K) — 28KB
• ex_650440.htm (EX-99.1) — 25KB
• logo.jpg (GRAPHIC) — 6KB
• 0001437749-24-011212.txt ( ) — 198KB
• crvo-20240401.xsd (EX-101.SCH) — 3KB
• crvo-20240401_def.xml (EX-101.DEF) — 11KB
• crvo-20240401_lab.xml (EX-101.LAB) — 15KB
• crvo-20240401_pre.xml (EX-101.PRE) — 11KB
• crvo20240405_8k_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition Earnings Press Release On April 1, 2024, CervoMed Inc. (the "Company," "we" or "us") issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued April 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 5, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel 3

View Full Filing

View this 8-K filing on SEC EDGAR